An observational cohort study of body mass index in pediatric vitiligo.

Competing Interests: The authors made the following disclosures: N.B.S. has been an advisor or received honoraria from Amryt, Incyte, Lilly, Regeneron/ Sanofi, and Verrica Pharmaceuticals. J.I.S. has received honoraria as a consultant and/or advisory board member for Abbvie, AObiome, Arcutis, Alamar, Amgen, Arena, Arcutis, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Union; speaker for Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; institution received grants from Galderma, Pfizer. The other authors have no conflicts of interest to disclose.